21,200 trials, and the base is widening
The cure stack kept growing today: 21,200 active cure-related trials, with 24 new research items and 63 new wire signals in the last 24 hours. In the clinic, durable combinations still matter — autologous stem cell transplant remains a strong standard in multiple myeloma, while China approved benmelstobart plus anlotinib as a first-line lung cancer regimen. But the day’s deeper signal is structural: the AI economy is increasingly being carried by capex, platform control is tightening, and even drug-discovery equities are under pressure to prove durable value. Progress is real, but the contest is shifting from isolated wins to systems that can sustain them. The window is still open.
The latest intelligence adds 24 new cure research items to a global base of 21,200 active cure-related trials, alongside 63 new wire signals in the last 24 hours.
Patients gain when durable regimens, better analysis tools like scAmp, and new approvals move from promise to practice, while investors and operators lose if AI and biotech narratives outrun clinical and commercial proof.
Watch whether the growing AI-capital cycle strengthens or narrows the broader economy, and whether today’s clinical gains translate into reproducible standards before momentum gets priced ahead of evidence.